Best-Link Bioscience completes ￥200M+ in Series B financing to accelerate global R&D of nano-conjugate drugs

Best-Link Bioscience, a biopharmaceutical enterprise dedicated to the research and development of novel nano-conjugate drugs and precision nanodelivery technologies, has completed a B-round financing exceeding RMB 200 million.

This round was jointly led by Hongcheng Investment and its affiliates (Sunshine Nohe, Hongyao Kechuang) and Yonghua Capital, with participation from TEDA Venture Capital and Casstar. Existing shareholders Lapam Capital and TigerYeah Capital continued their investment. Fenghe Capital served as the exclusive financial advisor for this financing round.

The raised funds will be primarily allocated to accelerating the advancement of core clinical pipelines, driving the R&D iteration of early-stage innovative projects, and expanding the interdisciplinary core team. This will further consolidate Best-Link Bioscience's global technological leadership in the field of nano-conjugate drugs and expedite the clinical translation and commercial deployment of breakthrough therapies.

Founded in May 2021, Best-Link Bioscience is a biopharmaceutical enterprise dedicated to the research and development of novel nano-conjugate drugs and precision nanodelivery technologies. The company has assembled an interdisciplinary R&D team spanning biology, chemistry, materials science, engineering, and nanotechnology. Focused on addressing long-standing key bottlenecks throughout the entire process from nanodrug development to industrialization, the team conducts systematic technological innovation and breakthroughs.

Based on a profound understanding of drug delivery challenges, Best-Link Bioscience has independently developed the NMPDC® technology platform. Grounded in rational design, this platform aims to systematically overcome the limitations of existing delivery systems. Its design holds potential for application across multiple tumor types, enabling efficient and stable delivery with significant deep tumor penetration. The NMPDC® platform can flexibly carry various types of payloads, demonstrating strong potential for expansion.

As the lead pipeline of the NMPDC® technology platform, the BL0020 injection addresses unmet therapeutic needs in highly aggressive solid tumors such as small cell lung cancer, thymic carcinoma, and pancreatic cancer. In the completed Phase I clinical study, the disease control rate (DCR) in small cell lung cancer patients reached 100%, with an objective response rate (ORR) of 83.3%. The majority of patients achieved partial response (PR) at the first tumor assessment, with 70% of PR patients experiencing significant tumor shrinkage (over 50% reduction). Additionally, brain metastases in small cell lung cancer patients showed significant reduction, achieving an ORR of 100% (including one case of complete response CR in brain metastases). The favorable safety profile of BL0020 lays a solid foundation for subsequent combination therapies and progression to first-line treatment. Relevant data have been disclosed in poster presentations at top international academic conferences, including the European Society for Medical Oncology (ESMO) Congress. Currently, BL0020 has successfully obtained Investigational New Drug (IND) clearance from the U.S. FDA and Orphan Drug Designation (ODD). The international multicenter Phase Ic/IIa clinical study (covering China, the United States, and Australia) has been initiated with the first patient dosed, marking a clearer path toward commercialization.

Another core pipeline, BL0175, is a first-in-class protein degrader nano-conjugate drug independently developed by Best-Link Bioscience. It has now entered international multicenter Phase I studies. Leveraging its unique nanodelivery design, the drug offers breakthrough advantages, including high stability in systemic circulation, efficient targeted accumulation in tumor tissues, tumor microenvironment-responsive release, and deep tumor penetration. Preclinical studies have shown that the BL0175 injection exhibits excellent single-agent antitumor activity in breast cancer animal models. Its combination therapy regimens further demonstrate significant synergistic effects. Early clinical studies have also shown initial efficacy, offering a new potential direction for the treatment of solid tumors.

From an overall strategic perspective, Best-Link Bioscience leverages its unique core technology platform to advance the research and development of multiple nano-conjugate drug pipelines in parallel. Its payloads cover various molecular types, including chemotherapeutic agents, protein degraders, and immune agonists, targeting multiple solid tumor indications. Through the parallel development of multiple projects in both preclinical and clinical stages, Best-Link Bioscience systematically validates the versatility and reliability of its platform technology in key areas such as delivery stability, tissue penetration, tumor accumulation efficiency, and scalable manufacturing. Currently, Best-Link Bioscience has accelerated multiple drug candidates into clinical stages. These advancements are expected to open new technological pathways for solid tumor treatment and provide patients with broader therapeutic options.